Valuation: Evelo Biosciences, Inc.

Market Cap 11.66L 10.12L 9L 9L 16.35L 11Cr 16.61L 1.11Cr 43.56L 5.54Cr 43.81L 42.84L 18Cr P/E 2021
-2.63x
P/E 2022 -1.23x
Enterprise Value 43.64L 37.86L 35.24L 32.38L 61.18L 42Cr 62.16L 4.15Cr 1.63Cr 21Cr 1.64Cr 1.6Cr 69Cr EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 day+29,900.00%
6 months+50.00%
Current year-40.00%
1 week 0
Extreme 0.0003
0
1 month 0
Extreme 0
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
13.93
5 years 0
Extreme 0
254.8
10 years 0
Extreme 0
398.57
Manager TitleAgeSince
Chief Executive Officer 64 21/11/2023
Director TitleAgeSince
Director/Board Member 64 21/11/2023
Date Insider Type Main position Quantity % Market Cap.
07/11/23 Fiscal year

Chief Financial Officer

14,811 0.0786%
07/11/23 Fiscal year

Chief Executive Officer

2,516 0.0134%
07/11/23 Fiscal year

Chief Technology Officer

16,413 0.0871%
Change 5-day change 1-year change 3-year change Capi.($)
+29,900.00%-.--%-40.00%-100.00% 5.69T
+2.35%+2.74%+33.41%+79.20% 5.65TCr
-0.21%-7.38%+25.34%+63.02% 5.36TCr
-2.44%+1.40%-15.74%-16.80% 2.29TCr
-2.85%-7.78%-8.09%+346.36% 2.14TCr
+2.49%-0.92%+20.31%-12.15% 2.03TCr
+0.79%-1.06%+29.29%-33.32% 1.76TCr
+0.58%-5.88%+16.30%+540.37% 1.47TCr
-5.25%-4.23%+46.41%+169.05% 1.33TCr
+3.41%-6.61%+163.08%+280.43% 1.35TCr
Average +2,989.89%-3.41%+27.03%+131.62% 2.34TCr
Weighted average by Cap. +0.23%-2.96%+28.67%+119.98%

Financials

2021 2022
Net sales - -
Net income -12Cr -11Cr -9.86Cr -9.06Cr -17Cr -1.17TCr -17Cr -116.18Cr -46Cr -580.43Cr -46Cr -45Cr -1.92TCr -11Cr -9.93Cr -9.25Cr -8.5Cr -16Cr -1.09TCr -16Cr -108.91Cr -43Cr -544.09Cr -43Cr -42Cr -1.8TCr
Net Debt -1.21Cr -1.05Cr -98.08L -90.12L -1.7Cr -115.88Cr -1.73Cr -12Cr -4.54Cr -58Cr -4.56Cr -4.46Cr -191.21Cr 31.98L 27.74L 25.82L 23.72L 44.83L 31Cr 45.55L 3.04Cr 1.19Cr 15Cr 1.2Cr 1.17Cr 50Cr
Logo Evelo Biosciences, Inc.
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.
Employees
66
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. EVLO Stock